REG - IXICO plc - Contract update

IXICOAnnouncement

20/10/2021 16:30

RNS Number : 7169P
  
IXICO plc
  
20 October 2021
  
 

 
IXICO plc
("IXICO" or the "Company")
 
Contract update
 
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has been notified by a client of an indefinite halt to the client's clinical trial following the receipt of unexpected preclinical data.
 
The client will therefore end its trial while it undertakes additional preclinical studies.  Contracted revenues for this trial represented £3.3m of the Company's order book as at 30 September 2021, of which the Company had expected to deliver £0.8m revenues in the financial year to 30 September 2022.
 
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR)
 
For further information please contact: 
 




IXICO plc


+44 (0) 20 3763 7498


 




Giulio Cerroni, Chief Executive Officer
Grant Nash, Chief Financial Officer


 


 




 


 


 




Cenkos Securities PLC (Nominated adviser and sole broker)


+44 (0) 20 7397 8900


 




Giles Balleny / Max Gould (Corporate Finance)


 




Michael F Johnson / Russell Kerr (Sales)


 




 


 




Walbrook PR Ltd


Tel: 020 7933 8780 or IXICO@walbrookpr.com




Paul McManus / Lianne Applegarth /


 




Alice Woodings


 



 
 
 
 
 



 
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.
 
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
UPDFLFFEIELIFIL